Within the Trump administration, a quiet contest over the soul of American health policy has surfaced through the brief firing and swift reinstatement of FDA vaccine regulator Vinay Prasad — a sequence of events that lasted two weeks but revealed fractures years in the making. On one side stands Robert F. Kennedy Jr.'s reform coalition, which sees itself as a genuine challenge to pharmaceutical industry power; on the other, MAGA influencer Laura Loomer, whose opposition to Prasad traced not to ideology but to her alignment with a drug manufacturer whose product Prasad had flagged as unsafe. Th
Raw Story
· Aug 14, 2025
· governance
· 2 min read
High
Sourcing: Characterized
Wiles intervenes in Trump administration power struggle between Kennedy and Loomer factions
◉
Politics & Governance
14718 related articles
Kazakhstan's ruling party dominates controlled election as Tokayev con…
Deutsche Welle · 100% match
Nancy Kassebaum Baker, pioneering GOP senator and first woman elected …
Fox News · 99% match
Kazakhstan's Balancing Act: Elections Cement Tokayev's Power Amid EU-R…
Deutsche Welle · 99% match
ACT unveils constitutional policy, quietly shelves failed Treaty Princ…
1News · 99% match
Trump quips protester's mom voting for him at South Carolina Graham ra…
Fox News · 99% match
Related Coverage
BBC News · Aug 25
England to build 70,000 social homes in first phase of £39bn housing plan
The UK government allocated nearly £10bn to build over 70,000 social and affordable homes across England over 10 years, …
BBC News · Aug 25 Hoy: Cancer screening push shouldn't fall to celebrities aloneOlympic cyclist Sir Chris Hoy argues that prostate cancer screening awareness should be a government responsibility, not…
The New York Times · Aug 25 Jelly Roll Marks 300-Pound Weight Loss With Trump Quip on KimmelCountry musician Jelly Roll marked a significant health achievement by losing 300 pounds, sharing the milestone while gu…
Al Jazeera · Aug 25 France and Saudi Arabia to jointly invest $7bn in three theme parks near ParisFrance and Saudi Arabia plan $7bn investment in three amusement parks near Paris, including a Dragon Ball Z-themed park …
Bias & Framing
⚖
Article frames internal Trump administration conflict as ideological battle between RFK Jr.'s health agenda and Laura Loomer's corporate interests, using language that favors Kennedy's faction.
Bias Direction
center-left
Confidence
HIGH
Conflict narrative that portrays Kennedy/Makary as principled health advocates versus Loomer as a corporate-aligned disruptor; uses insider sourcing to legitimize Kennedy's position while characterizing Loomer's actions as divisive.
corporate-aligned faction
corporate interests
insufficiently loyal
split the MAHA and MAGA coalition
trained her sights on
MAGA influencer
Laura Loomer's direct response or detailed explanation of her concerns about Prasad
Sarepta Therapeutics' perspective on the drug safety allegations
Detailed analysis of Prasad's actual qualifications and track record
Perspective from those who may agree with Loomer's loyalty concerns
Context on whether Prasad's pandemic-era social media posts are relevant to current role
Geopolitical Impact
🌎
Internal Trump administration power struggle between RFK Jr.'s health reform agenda and Laura Loomer's corporate-aligned faction reveals fissures in MAGA coalition, with chief of staff Wiles mediating conflicts over FDA personnel and pharmaceutical policy.
Escalation Risk
low
Confidence
MED
United States
Domestic U.S. power struggle with no direct international implications. However, reflects broader tensions within Trump administration between populist health reformers (Kennedy faction) and corporate-aligned influencers (Loomer faction), potentially affecting U.S. regulatory policy direction and pharmaceutical industry influence on government.
Similar to internal Reagan administration conflicts between ideological conservatives and pragmatists over policy implementation, though this involves regulatory capture concerns rather than Cold War strategy.
Economic Lens
📈
Internal Trump administration conflict between RFK Jr.'s health reform agenda and corporate-aligned faction creates regulatory uncertainty for pharmaceutical and healthcare sectors.
Market Signal
mixed
Confidence
MED
Pharmaceutical Manufacturing
Healthcare/Medical Devices
Food and Drug Administration (Regulatory)
Biotechnology
Medical Equipment
Consumers face uncertainty regarding FDA drug approval standards and safety oversight. Potential for inconsistent regulatory enforcement depending on which faction gains influence, affecting drug availability, pricing, and safety protocols.
FDA regulatory direction remains unstable with competing agendas: RFK Jr.'s health-focused reforms versus corporate pharmaceutical interests. Risk of politicized drug approvals/rejections based on internal power dynamics rather than scientific merit. Potential for Congressional scrutiny of FDA independence and executive branch interference.